A Breakdown of Recent 340B Program Changes

    October 2014

    Following explosive growth, harsh accusations of program abuse, Congressional inquiries, a lawsuit, an interpretive rule and forthcoming mega-rule, the 340B Drug Discount Program seems to be getting a lot of attention. So what’s all the fuss about? There are a lot of moving parts, but as a hospital general counsel, this could represent millions to your institution’s bottom line. This article provides the reasons to make sure you’re not caught off-guard.

    “A Breakdown of Recent 340B Program Changes: Learn How 340B Drug Discount Program Changes Could Negatively Impact Providers’ Bottom Lines,” by Squire Patton Boggs principal Eugenia Pierson, was recently published in The Health Care Law Roundtable’s third quarter edition of the General Counsel Agenda – a publication written for the hospital and health system in-house counsel audience.